Booth BP - Search Results

1

Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice.

Grillo JA, Zhao P, Bullock J, Booth BP, Lu M, Robie-Suh K, Berglund EG, Pang KS, Rahman A, Zhang L, Lesko LJ, Huang SM. Grillo JA, et al. Among authors: booth bp. Biopharm Drug Dispos. 2012 Mar;33(2):99-110. doi: 10.1002/bdd.1771. Epub 2012 Mar 4. Biopharm Drug Dispos. 2012. PMID: 22270945

2

Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.

Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, Song P, Brar SS, Madabushi R, Wu TC, Booth BP, Rahman NA, Reynolds KS, Gil Berglund E, Lesko LJ, Huang SM. Zhao P, et al. Among authors: booth bp. Clin Pharmacol Ther. 2011 Feb;89(2):259-67. doi: 10.1038/clpt.2010.298. Epub 2010 Dec 29. Clin Pharmacol Ther. 2011. PMID: 21191381

3

Toward greater insights on pharmacokinetics and exposure-response relationships for therapeutic biologics in oncology drug development.

Wang Y, Booth B, Rahman A, Kim G, Huang SM, Zineh I. Wang Y, et al. Clin Pharmacol Ther. 2017 May;101(5):582-584. doi: 10.1002/cpt.628. Epub 2017 Mar 15. Clin Pharmacol Ther. 2017. PMID: 28090657 Review.

4

Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients.

Booth BP, Rahman A, Dagher R, Griebel D, Lennon S, Fuller D, Sahajwalla C, Mehta M, Gobburu JV. Booth BP, et al. J Clin Pharmacol. 2007 Jan;47(1):101-11. doi: 10.1177/0091270006295789. J Clin Pharmacol. 2007. PMID: 17192508 Clinical Trial.

5

Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis.

Liu C, Yu J, Li H, Liu J, Xu Y, Song P, Liu Q, Zhao H, Xu J, Maher VE, Booth BP, Kim G, Rahman A, Wang Y. Liu C, et al. Among authors: booth bp. Clin Pharmacol Ther. 2017 May;101(5):657-666. doi: 10.1002/cpt.656. Epub 2017 Mar 22. Clin Pharmacol Ther. 2017. PMID: 28182273

6

The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.

Ramchandani RP, Wang Y, Booth BP, Ibrahim A, Johnson JR, Rahman A, Mehta M, Innocenti F, Ratain MJ, Gobburu JV. Ramchandani RP, et al. Among authors: booth bp. J Clin Pharmacol. 2007 Jan;47(1):78-86. doi: 10.1177/0091270006295060. J Clin Pharmacol. 2007. PMID: 17192505

7

The combination of exposure-response and case-control analyses in regulatory decision making.

Yang J, Zhao H, Garnett C, Rahman A, Gobburu JV, Pierce W, Schechter G, Summers J, Keegan P, Booth B, Wang Y. Yang J, et al. J Clin Pharmacol. 2013 Feb;53(2):160-6. doi: 10.1177/0091270012445206. Epub 2013 Jan 24. J Clin Pharmacol. 2013. PMID: 23436261 Clinical Trial.

8

Current Perspectives on Ligand-Binding Assay Practices in the Quantification of Circulating Therapeutic Proteins for Biosimilar Biological Product Development.

Thway TM, Wang YM, Booth BP, Maxfield K, Huang SM, Zineh I. Thway TM, et al. Among authors: booth bp. AAPS J. 2019 Dec 19;22(1):15. doi: 10.1208/s12248-019-0397-8. AAPS J. 2019. PMID: 31858313

9

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response.

Li H, Yu J, Liu C, Liu J, Subramaniam S, Zhao H, Blumenthal GM, Turner DC, Li C, Ahamadi M, de Greef R, Chatterjee M, Kondic AG, Stone JA, Booth BP, Keegan P, Rahman A, Wang Y. Li H, et al. Among authors: booth bp. J Pharmacokinet Pharmacodyn. 2017 Oct;44(5):403-414. doi: 10.1007/s10928-017-9528-y. Epub 2017 Jun 1. J Pharmacokinet Pharmacodyn. 2017. PMID: 28573468

10

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.

Brave M, Goodman V, Kaminskas E, Farrell A, Timmer W, Pope S, Harapanhalli R, Saber H, Morse D, Bullock J, Men A, Noory C, Ramchandani R, Kenna L, Booth B, Gobburu J, Jiang X, Sridhara R, Justice R, Pazdur R. Brave M, et al. Clin Cancer Res. 2008 Jan 15;14(2):352-9. doi: 10.1158/1078-0432.CCR-07-4175. Clin Cancer Res. 2008. PMID: 18223208

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

71 results

Search Page

Filters